ABOUT US
We are a Swiss pharmaceutical wholesaler, specialized in sourcing and delivering pharma products, medical devices and drugs from and to all over the world.
Here in ELIXI we consider fast delivery of life-saving medicines as a basic but mandatory human value.
QUALITY
As a pharmaceutical wholesaler, working directly with pharma manufactures, medicine distributors, hospitals and clinics, we comply with the newest Standard Operating Procedures (SOPs), which guide our professional team step-by-step in all of ELIXI’s activities ensuring the highest quality standards required by the pharma world.
WHO WE ARE
We deliver pharma products from Switzerland and from all over the world.
Our team in ELIXI International has a solid experience in the distribution of medical products.
History has taught us to prioritize the urgency that lays behind the need of supplying a drug in the fastest possible way. Here in ELIXI we consider fast delivery as a basic but mandatory human value. In order to achieve this goal, we developed a simple but qualified process made of synergies with long lasting partners who, like us, believe in people and not in machines.
NEWS
Janssen Announces U.S. FDA Approval of SYMTUZA, the First and Only Complete Darunavir-Based Single-Tablet Regimen for the Treatment of HIV-1 Infection
The Janssen Pharmaceutical Companies of Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved…
Third Novartis Phase III trial shows Kisqali (ribociclib) combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer
Novartis has announced positive results from the third Phase III trial of Kisqali (ribociclib) in advanced or metastatic breast cancer. MONALEESA-3…
FDA approves TPOXX (tecovirimat) the first drug with an indication for treatment of smallpox
The U.S. Food and Drug Administration today approved TPOXX (tecovirimat), the first drug with an indication for treatment of smallpox.…
Veyvondi, vonicog alfa, for the treatment of Willebrand disease.
On 28 June 2018, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing…
Verkazia, (ciclosporin), new medicine for rare form of eye allergy in children and teenagers
The European Medicines Agency (EMA) has recommended granting a marketing authorisation in the European Union (EU) for Verkazia (ciclosporin), a medicine that…
Genentech Announces Submission of Supplemental New Drug Application for Venclexta (venetoclax) for People With Previously Untreated Acute Myeloid Leukemia who are Ineligible for Intensive Chemotherapy
Genentech has announced submission of a supplemental New Drug Application to the U.S. Food and Drug Administration (FDA) for Venclexta (venetoclax),…
Ulipristal Acetate, a pre-operative treatment of uterine fibroids, gets a positive opinion from the Committee for Medicinal Products for Human Use (CHMP)
On 28 June 2018, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing…
FDA approves Doptelet ( avatrombopag) for patients with chronic liver disease who have low blood platelets and are undergoing a medical procedure
The U.S. Food and Drug Administration has approved Doptelet (avatrombopag) tablets to treat low blood platelet count (thrombocytopenia) in adults…
FDA APPROVES XEOMIN (INCOBOTULINUMTOXINA) FOR ADULT PATIENTS WITH SIALORRHEA
The FDA has approved the supplemental Biologics License Application (sBLA) for XEOMIN (incobotulinumtoxinA) for the treatment of chronic sialorrhea, or excessive…
First two CAR-T cell medicines, Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel) recommended for approval in the European Union
The European Medicines Agency (EMA) has recommended the first two marketing authorisations for chimeric antigen receptors (CAR) T-cells medicines in the European Union…
Xeljanz (tofacitinib citrate) receives marketing authorisation in the EU for active Psoriatic Arthritis
The European Commission has approved XELJANZ (tofacitinib citrate) 5 mg twice daily (BID) in combination with methotrexate (MTX) for the…
CONTACT US
ELIXI International SA
Piazza Boffalora 4
6830 Chiasso / Switzerland
Tel: +41 91 682 20 40